The data bolsters Eli Lilly’s position in the budding weight loss drug market and establishes the company as a formidable competitor to Novo Nordisk.
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
Posted in Uncategorized.